Periodic Reporting for period 1 - AMNIOGEL (Extracellular matrix derived products from human placenta to engineer bone microtissues for in vitro disease models.)
Période du rapport: 2020-09-01 au 2022-10-31
The aim of ‘AMNIOGEL’ is the development of human extracellular matrix (ECM) based materials, as radically innovative, highly versatile human-derived platforms for 3D cell culture, microtissue development and disease models establishment. In particular, we will develop 3D disease models that could be used as an enabling tool for personalized drug discovery, increasing our understanding of the mechanisms behind bone cancer. The proposed cutting edge technology enables the culture of human cells in a physiologically relevant microenvironment for applications in cell culture research, drug screening and development, cancer research, tissue engineering, replacement of animal testing and therapeutic applications. The potential of this technology to reduce or completely replace use of animals for biological screenings is expected to have a significant impact in the 3D cell culture market and pharmaceutical industry by accelerating drug screening and development reducing associated costs. The innovation potential of our products is based on the fact that contain human biochemical cues (vital for cell function), is a complete xeno-free solution (avoids contamination) for human cell culture and easy to manipulate. It is worth mentioning that offers the possibility to be personalised (using the patient’s own ECM) according to the customer needs. Moreover, our culture substrates are easily processed in multiple geometries and in microarrays amenable to ‘organ-on- a-chip’ systems designed for high-throughput screening (HTS) applications.